[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection]
- PMID: 20172621
- DOI: 10.1016/j.jfo.2010.01.009
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection]
Abstract
The complex immunological effects of interferon and ribavirin therapy in hepatitis C virus may also exacerbate or trigger the development of autoimmunity. A rare case of Vogt-Koyanagi-Harada disease associated with ribavirin and interferon-alpha treatment for chronic hepatitis C infection is presented. The potential role of interferon and/or ribavirin therapy is discussed. Physicians should be aware of the association between interferon-alpha 2a and ribavirin use for hepatitis C infection and the development of Harada disease. This severe ophthalmological complication requires close follow-up of hepatitis C virus-infected patients on interferon-alpha treatment.
Similar articles
-
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.J Infect. 2006 Feb;52(2):e59-61. doi: 10.1016/j.jinf.2005.05.005. Epub 2005 Jun 13. J Infect. 2006. PMID: 15951019
-
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.Int Ophthalmol. 2010 Oct;30(5):611-3. doi: 10.1007/s10792-010-9357-0. Epub 2010 Feb 23. Int Ophthalmol. 2010. PMID: 20177954
-
Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.J Viral Hepat. 2003 Nov;10(6):467-70. doi: 10.1046/j.1365-2893.2003.00456.x. J Viral Hepat. 2003. PMID: 14633182
-
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.J Gastroenterol. 2004 Nov;39(11):1106-9. doi: 10.1007/s00535-004-1452-4. J Gastroenterol. 2004. PMID: 15580406 Review.
-
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12. Ocul Immunol Inflamm. 2019. PMID: 29023176 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources